<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="â€¢Early identification of rising cytokine storm and multilevel course of" exact="treatment" post="is imperative. â€¢Adjunctive treatment improves the success in fight"/>
 <result pre="cytokine storm and multilevel course of treatment is imperative. â€¢Adjunctive" exact="treatment" post="improves the success in fight with consequences of CRS."/>
 <result pre="patients. Early identification of rising state and multilevel course of" exact="treatment" post="is imperative. The most widely used molecule for systemic"/>
 <result pre="treatment is imperative. The most widely used molecule for systemic" exact="treatment" post="remains tocilizumab. Except for anti IL-6 treatment, contemporary research"/>
 <result pre="opens the possibilities for combination of pharmaceutical, non-pharmaceutical and adjunctive" exact="treatment" post="in a successful fight with consequences of cytokine storm."/>
 <result pre="â€œcytokine stormâ€� is mainly connected to COVID-19, many hypothesis concerning" exact="treatment" post="modalities have been rising in the last fifteen years."/>
 <result pre="the anti T-cell antibody muromonab-CD3 was introduced as an immunosuppressive" exact="treatment" post="for solid organ transplantation [4]. Yet, Vegh et al."/>
 <result pre="theralizumab [11], nivolumab [12], obinutuzumab [13], brentuximab [14]. Anticancer non-protein-based" exact="treatment" post="with oxaliplatin [15] and IMiDs (lenalidomide) [16] can activate"/>
 <result pre="Spanish flu in 1919 through dengue, Ebola to corona virus" exact="infection" post="in 2020 [17]. CRS has been observed also in"/>
 <result pre="allergen, or cytotoxic agent when possible, should be eliminated. Antimicrobial" exact="treatment" post="is indicated in any form of cytokine storm if"/>
 <result pre="storm if contributing pathogen is suspected. Even though simultaneous antimicrobial" exact="treatment" post="is not the topic of presented contribution, many of"/>
 <result pre="to understand for restoring immunologic balance, the main focus in" exact="treatment" post="should be directed towards final common pathway. At that"/>
 <result pre="contributes to broadening of immune mediated inflammation [24]. Therefore, multilevel" exact="treatment" post="opportunities should be a challenge (Fig. 1 ). Fig."/>
 <result pre="strikes suddenly and the main goal, after starting intensive care" exact="treatment" post="and targeting the elimination environmental trigger (if possible), is"/>
 <result pre="inflammatory cytokines. It is expected to be effective in the" exact="treatment" post="of cytokine storm in viral infections (SARS-CoV-2). It is"/>
 <result pre="to estimate the effect of such treatment. 2.3 Targeted (immunomodulatory)" exact="treatment" post="Although immunomodulatory therapy is not routinely recommended, majority of"/>
 <result pre="of biological drugs are TNF-Î± blockers, but their role in" exact="treatment" post="of cytokine storm remains unclear. Although TNF-Î± inhibiting agents"/>
 <result pre="to be effective in cytokine dysbalance, other report worsening during" exact="treatment" post="with TNF-Î± inhibiting agents, the published results have been"/>
 <result pre="IL-6 Tocilizumab remains the most commonly used therapy for systemic" exact="treatment" post="of CRS. Multiple studies conï¬�rmed the correlation of peak"/>
 <result pre="severity of CRS leading to the approval of tocilizumab for" exact="treatment" post="of CRS concurrent with the approval of tisagenlecleucel, CAR"/>
 <result pre="opened clinical trial â€œEfficacy and safety of tocilizumab in the" exact="treatment" post="of SARS-Cov-2 related pneumonia (TOSCA)â€� (NCT04332913) might show a"/>
 <result pre="storm merit reconsideration of this therapeutic agent as a potential" exact="treatment" post="option for CRS. This cytokine is not consistently elevated"/>
 <result pre="antibody directed against IL-1Î² [37]. Although canakinumab is an effective" exact="treatment" post="in SJIA, it does not appear to have a"/>
 <result pre="IL-18 can be a therapeutic target not only for the" exact="treatment" post="of inflammatory diseases but also for cytokine storm. Gabay"/>
 <result pre="offer another possibility of therapy within the scope of anti-cytokine" exact="treatment" post="such as NLRC4-related macrophage activation syndrome, the etiological factor"/>
 <result pre="IL-17, anti IL-17R and anti IL-12/23p40) available; however, the antibody-based" exact="treatment" post="is expensive and has only a narrow spectrum of"/>
 <result pre="and has only a narrow spectrum of effects [39]. Therefore," exact="treatment" post="by JAK inhibitors is tested to restrict the pro-inflammatory"/>
 <result pre="are available on ClinicalTrial.gov (accessed 26 August 2020) focusing on" exact="treatment" post="COVID-19 associated cytokine storm with ruxolitinib as monotherapy (NCT04362137,"/>
 <result pre="profile. Two Italian studies (NCT04320277, NCT04358614) are registered for clinical" exact="testing" post="of baricitinib and its effect on reduction of cytokine"/>
 <result pre="for myeloproliferative neoplasms. Wu and Yang [39] found that fedratinib" exact="treatment" post="decreased in vitro the expression of IL-17 by murine"/>
 <result pre="information concerning cytokine release syndrome has been obtained. 2.4 Adjunctive" exact="treatment" post="Solitary trials registered on Clinical trial.gov are focused on"/>
 <result pre="(N-acetylcysteine and erdosteine) encourages us to use them in the" exact="treatment" post="of cytokine storm. N-acetylcysteine (NAC) serves as a prodrug"/>
 <result pre="its anti-inflammatory effects, it may also be effective for the" exact="treatment" post="of cytokine storm induced by severe influenza [44]. Similar"/>
 <result pre="that sodium cromoglycate protects mice effectively from death after viral" exact="infection" post="by alleviating inflammatory injury via its function as an"/>
 <result pre="of intensive rise of cytokine storm and search for appropriate" exact="treatment" post="options. Some preclinical studies are encouraging. Decreased production of"/>
 <result pre="conditions. Early identification of rising state and multilevel course of" exact="treatment" post="is imperative. Strictly immunologic approach is necessary mainly when"/>
 <result pre="treatment. At present, the most widely used molecule for systemic" exact="treatment" post="of CRS remains tocilizumab. Its FDA and EMA approval"/>
 <result pre="CRS remains tocilizumab. Its FDA and EMA approval for the" exact="treatment" post="of cytokine storm after CAR-T cell therapy gives us"/>
 <result pre="us possibilities for combination of pharmaceutical and non-pharmaceutical and adjunctive" exact="treatment" post="in successful fight with consequences of CRS. Further work"/>
</results>
